Wound Unhealing as a Grave Issue of Cancer

Ming C. Liau *

CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.

Christine L. Craig

CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.

Linda L. Baker

CDA Therapeutics, Inc., 3308 Sky Run Court, Missouri City, TX 77459, USA.

*Author to whom correspondence should be addressed.


Abstract

Wound healing requires the proliferation and the terminal differentiation of PSCs, the most primitive stem cells expressing abnormal differentiation enzymes (MEs). Wound if not healed properly, PSCs may be forced to evolve into cancer stem cells (CSCs), and then to progress to faster growing cancer cells (CCs). Our carcinogenesis studies revealed that the numerous tiny preneoplastic hyperplastic nodules appeared in response to carcinogen challenge were the attempt of the liver to repair the damages created by carcinogen. These nodules represented the proliferation of PSCs displaying abnormal MEs. Most of these nodules disappeared when the damages were repaired. Only a few nodules which were not successful repaired, later developed to become large carcinomas. The employment of phenylacetylglutamine, which was an effective anti-cachexia chemical to protect the functionality of chemo-surveillance, could prevent carcinogenesis induced by potent carcinogens. These studies clearly demonstrated that carcinomas developed if wounds were not efficiently healed.

Perpetual proliferation of CCs was the most outstanding feature of cancer. Stop proliferation of CCs naturally became the top choice of cancer therapy. There were two options to stop proliferation of CCs: one by killing of CCs and the other by induction of terminal differentiation of CCs. Cancer was also made up by CSCs as a minor component. The option by killing of CCs was the choice of cancer establishments, which displayed the feature as anti-wound healing, clearly a wrong choice because cancer was caused by wound unhealing. The option by the induction of terminal differentiation was the choice of the nature which created chemo-surveillance to ensure perfection of wound healing to avoid cancer. This option displayed the feature as pro-wound healing, clearly the right indication of cancer therapy. CSCs play a major role on the fatal effects of cancer. The effectiveness of cancer therapy depends heavily on the ability to eradicate CSCs. Therapies based on killing of CCs were ineffective against CSCs because these cells were protected by drug resistance and anti-apoptosis mechanisms, whereas the induction of terminal differentiation was a critical mechanism of wound healing very effective to eradicate CSCs. Thus, the option by the induction of terminal differentiation was the right choice for cancer therapy.

Keywords: Cancer moonshot, cancer therapy, terminal differentiation, CDA formulations, CSCs, PSCs, wound healing


How to Cite

Liau , M. C., Craig , C. L., & Baker , L. L. (2023). Wound Unhealing as a Grave Issue of Cancer. International Research Journal of Oncology, 6(1), 97–103. Retrieved from https://journalirjo.com/index.php/IRJO/article/view/128

Downloads

Download data is not yet available.

References

Google search. Cancer statistics-NCI.

Liau MC, Fruehauf JP. It has been half a century since President Nixon declared war on cancer: Destabilization of abnormal methylation enzymes has the blessing of the nature to win the war on cancer. Adv Complement Alt Med. 2020;6(1):538-539.

Liau MC, Fruehauf JP. Cancer moonshot: Moonshot as a magic code to guide successful solutions of tough challenges such as cancer. Intl J Res Oncol. 2023:2(1):1-5.

Liau MC, Craig CL. Baker LL. Cancer moonshot to bring hope to desperate cancer patients. Intl Res J Oncol. 2023;7(2):13-18.

Virchow R. Die cellular parthologie in ihrer begrundung auf physiologische und pathologische gewebelehve. Hirschwold. 1858:16:440.

Dvorak HF. Tumors: Wound that do not heal. N Engl J Med. 1986;315(26):1650-1659.

MacCarthy-Morrough L, Martin P. The hallmarks of cancer are also the hallmarks of wound healing. Science Signaling. 2020;13:648.

Liau MC, Lin GW, Hurlbert RB. Partial purification and characterization of tumor and liver S-adenosylmethionine synthetases. Cancer Res. 1977;37(2):427-435.

Liau MC, Chang CF, Giovanella BC. Demonstration of an altered S-adenosylmethionine synthetase in human malignant tumors xenografted into athymic nude mice. J Natl Cancer Res. 1980:64(5):1071-1075.

Liau MC, Zhuang P, Chiou GCY. Identification of the tumor factor of abnormal methylation enzymes as the catalytic subunit of telomerase. Clin Oncol Cancer Res. 2010;7(2):86-96.

Liau MC, Szopa M, Burzynski B, Burzynski SR. Chemo-surveillance: A novel concept of the natural defense mechanism against cancer. Drug Exptl Clin Res. 1989; 13(Suppl. 1):2-82.

Liau MC, Baker LL. The functionality of chemo-surveillance dictates the success of wound healing as well as cancer therapy. Nov Res Sci. 2021;7(2):1-3.

Liau MC, Craig CL. Chemo-surveillance as a natural mechanism to ensure perfection of wound healing to avoid cancer evolution and to cure cancer. In: New Horizons in Medicine and Medical Research. 2022;6. Chapter 3. Print ISBN: 978-93-5547-607-4.

Liau MC, Baker LL. Destruction promotes the proliferation of progenitor stem cells and cancer stem cells. Therefore, non-destruction is a better strategy for cancer therapy. J Pharmacol Pharmaceu Pharmacovig. 2020;4:029.

DOI: 10.24966/PPP.5649/100029

Liau MC, Lee SS, Burzynski SR. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Intl J Exptl Clin Chemother. 1989;2: 187-199.

Liau MC, Craig CL. On the mechanism of wound healing and the impact of wound on cancer evolution and cancer therapy. Intl Res J Oncol. 2021;5(3):25-31.

Liau MC, Baker LL. Wound healing, evolution of cancer and war on cancer. Intl Res J Oncol. 2021;4(3):13-20.

Liiau MC, Craig CL. No scar as an indication of perfect wound healing, ugly scar as imperfect wound healing and cancer as failed wound healing. J Cancer Tumor Intl. 2022;12(1):29-34.

Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes: Nature’s way to eradicate cancer stem cells. Online J Complement Alt Med. 2019;2:1-6.

Kudo Y, Tateishi K, Yamamoto K, Yamamoto S, Asaoka Y, Ijichi H, et al. Loss of 5-hydroxymethylcytosine is accompanied with malignant cellular transformation. Cancer Sci. 2012;103:670-676.

Ficz GM, Giben JG. Loss of 5-hydroxymethlylcytosine in cancer: Cause or consequence? Genomics. 2014; 104:352-357.

Liau MC, Craig CL. Wound healing metabolites to heal cancer and unhealed wounds. Intl Res J Oncol.2022;6(3):8-20.

Liau MC, Baker LL. The impact of COVID-19 pandemic on cancer patients. Intl Res J Oncol. 2022;6(4):13-17.

Liau MC, Craig CL, Baker LL. Wound healing process as the most appropriate modality of cancer therapy. Eur J Applied Sci. 2023;11(1):463-471,

Liau MC, Chang CF, Becker FF. Alteration of S-adenosylmethionine synthetases during chemical hepatocarcinogenesis and in resulting carcinomas. Cancer Res. 1979; 39:2113-2119.

Kamparath BN, Liau MC, Burzynski B, Burzyneki SR. Chemoprevention by Antineoplaston A10 of bezo-a-pyrene-induced pulmonary neoplasia. Drug Expt. Clin Res. 13(Suppl. 1):51-56.

Kamparath BN, Liau MC, Burzynski B, Burzynski SR. Protective effect of Antineoplasrton A10 in hepatocarcinogenesis induced by aflatoxin B1. Intl J Tiss React. 1990;12(Suppl.): 43-50.

Liau MC. Pharmaceutical composition inducing cancer cell differentiation and the use for treatment and prevention of cancer thereof. US Patent 7232578 B2; 2007.

Liau MC, Kim JH, Fruehauf JP. Destabilization of abnormal methylation enzymes to combat cancer: The nature’s choice to win the war on cancer. Lambert Academic Publishing. 2020;978-620-2-66889-7.

Liau MC, Fruehauf PA, Zheng ZH, Fruehauf JP. Development of synthetic cell differentiation agent formulations for the prevention and therapy of cancer via targeting of cancer stem cells. Cancer Stu Ther J. 2019;4(1):1-15.

Morley JE. Hormone, aging and endocrine in the elderly. In: Felig P, Frohman LA, “Endocrine and Metabolism” (4th ed.), McGrow Hill. Inc. Medical Publishing Division, New York: page 1455-1482.

Liau MC, Fruehauf JP. Think hard on destabilization of abnormal methylation enzymes to combat cancer: It can be life saving. Adv Complement Alt Med. 2019;5(3):464-465.

Liau MC, Baker LL. Cancer patients’ lives matter. Adv Complement Alt Med. 2021;6(5):638-640.

Williamson PJ, Kruger AR, Reynolds PJ, Hamlin TJ, Oscier DG. Establishing the incidence of myelodysplastic syndromes. Br J Haemato. 1994;87(4):743-745.

Boula A, Voulgarelis M, Giannouli S, Katrinakis G, Psyllaki M, Pontikoglou C, et al. Effect of CA2 antitumor necrosis factor-a antibody therapy on hematopoiesis of patients with myelodysplastic syndromes. Clin Cancer Res. 2006;12(10):3099-3108.

Woll PS, Kjallquist U, Chowdhurry O, Doolittle H, Wedge DC, Thongjuea S, et al. Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo. Cancer Cell. 2014;25(6):794-808.

Prassana P, Shack S, Wilson VL, Samid D. Phenylacetate in chemoprevention of 5-aza-2’-deoxycitidine-induced carcinogenesis. Clin Cancer Res. 1995;1(18):865-871.

Gaudet F, Hodgson JG, Eden A, Jackson-Grusby L, Dausman J, Grau JW, et al. Induction of tumor in mice by genomic hypomethylation. Science. 2003; 300(5618):489-492.

Palii SS, van Emburgh BO, Sankpal UT, Brown KD, Robertson KD. DNA methylation inhibitor 5-aza-2’-deoxycytidine induces reversible DNA damage that is distinctly influenced by DNA-methyl-transferase 1 and 3B. Mol Cell Biol. 2008;28(2):752-771.

Kizietepe T, Hedishima T, Catley L, Raje N. Yasui H, Shiraishi N, et al. 5-Azacytidine, a methyltransferase inhibitor, induces ATR-mediated DNA-double strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicine and bortezomib against multiple myeloma cells. Mol Cancer Ther. 2007;6(6):1718-1727.

Yang Q, Wu F, Wang F, Cai K, Zhang Y, Sun Q, et al. Impact of DNA methyltransferase inhibitor 5-azacytidine on cardiac development of zebrafish in vivo and cardiomyocyte proliferation, apoptosis, and the homeostasis of gene expression in vitro. J Cell Biochem. 2019;120(10):17459-17471.

Liau MC, Fruehauf JP. The winner of the contest to eradicate cancer stem cells win the contest of cancer therapies: The winner is cell differentiation agent formulations. Adv Complement Alt Med. 2020;5(4):476-478.

Liau MC, Baker LL. Eradication of cancer stem cells to win the war on cancer. Nov Res Sci. 2021;6(5):1-3.

Liau MC, Baker LL. Cell differentiation agent formulations to win the war on cancer. Cancer Sci Res. 2022;5(2):1-4.

Liau MC, Fruehauf JP. Winning formulas to fulfill cancer moonshot. Intl J Res Oncol. 2022;1(1):1-5.

Liau MC, Kim JH, Fruehauf JP. Potentiation of ATRA activity in HL-60 cells by targeting methylation enzymes. J Pharmacol Pharmaceu Pharmacovig. 2019;3:009. DOI: 10.24966/PPP-5649/100009

Liau MC, Kim JH, Fruehauf JP. In pursuance of differentiation inducers to combat cancer via targeting of abnormal methylation enzymes. J Cancer Tumor Intl. 2020;10(2):19-47.

Liau MC, Kim JH, Fruehauf JP. Arachidonic acid and its metabolites as the surveillance differentiation inducers to protect healthy people from becoming cancer patients. Clin Pharmacol Toxicol Res. 2021;4(1):7-10.